Everything You Need to Know About Leqembi Maintenance and Medicare
After Leqembi removes amyloid plaques from the brain, treatment isn't over. The brain continues to produce beta-amyloid every day, and in Alzheimer's disease a small amount escapes the brain's natural clearance systems. Without continued treatment, these molecules can gradually accumulate again, forming toxic oligomers, protofibrils, and eventually new plaques. This article explains why maintenance therapy is essential after the initial 18 months of Leqembi, compares monthly IV infusions with the FDA-approved IQLIK® self-injection, and provides a practical guide to Medicare Part B and Part D coverage, specialty pharmacies, formularies, prior authorization, and out-of-pocket costs so you can make informed decisions about your long-term treatment options.
How Leqembi and Kisunla Fight Alzheimer's in Different Ways
A diagnosis of Alzheimer's no longer means there are no treatment options. Two FDA-approved drugs, Leqembi and Kisunla, can slow the disease for people diagnosed early, but they work differently. Understanding how beta-amyloid changes from harmless protein fragments into toxic oligomers, protofibrils, plaques, and eventually tau tangles can help patients and families make more informed treatment decisions.
Leqembi IQLIK and Medicare: Everything You Need to Know Before You Switch
Should you stay on Leqembi infusions or switch to the new at-home IQLIK injection? That decision involves much more than convenience. Medicare covers the two treatments differently, and understanding Part B, Part D, specialty pharmacies, formularies, prior authorization, and the new annual out-of-pocket cap can save you both time and money. This practical guide explains the process step by step so people living with early Alzheimer's disease and their caregivers can make informed decisions before their first IQLIK prescription.
Leqembi = Plaque Free Brain and a Promising Future
Imagine being told you have Alzheimer's disease—and then, two years later, learning that the beta-amyloid plaques once filling your brain are no longer detectable on a PET scan. Until recently, that outcome would have seemed impossible. Thanks to early diagnosis and treatment with Leqembi, it became my reality. This is not a story about a cure. It is a story about what can happen when Alzheimer's is detected early enough for today's disease-modifying treatments to make a difference. It is also a story of gratitude—to the scientists who made this breakthrough possible—and a reminder that every adult over 60 should ask for a cognitive assessment before symptoms become impossible to ignore.
How Leqembi’s Multi-Target Strategy Fights Alzheimer’s
For decades, Alzheimer's treatments could do little more than ease symptoms while the disease continued its relentless attack on the brain. Leqembi represents a different approach. Rather than simply treating the consequences of Alzheimer's, it targets the disease itself by attaching to harmful beta-amyloid proteins at multiple stages of their development—from the smallest, most toxic clusters to fully formed plaques. By interrupting this destructive process early and continuing to remove existing amyloid, Leqembi gives the brain a better opportunity to protect neurons, preserve memory, and maintain the connections that define who we are. Understanding why this matters begins with understanding how Alzheimer's damages the brain.